JNJ
Johnson & Johnson
Drug Manufacturers - General · Healthcare · United States
275.20
close · 2026-10-29
value
24
cheaper than peers24
quality
80
stronger fundamentals80
ranked against
Healthcare
value
quality
547 peerssector comparisonwide variation
Value inputs
| measure | company | vs peers |
| price to sales | 6.12× | 38 |
| EV to EBITDA | 19.04× | 38 |
| forward P/E | 23.69× | 38 |
| price to book | 8.13× | 21 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 29.2% | 93 |
| return on equity | 25.7% | 91 |
| revenue growth | 6.6% | 43 |
| debt to equity | 57.7% | 37 |
4 of 4 measures available
Facts
| market cap | $662B |
| free cash flow | $16.89B |
| employees | 138,200 |
| first trade | 1962-01-02 |
| next earnings | 2026-10-13 |
| fundamentals updated | 2026-10-13 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 11.03 | 5.79 | 13.72 | 6.73 |
| free cash flow | $19.31B | $18.06B | $17.78B | $17.18B |
| net income | $26.80B | $14.07B | $35.15B | $17.94B |
| revenue | $94.19B | $88.82B | $85.16B | $79.99B |
| unusual items | $5.89B | -$7.04B | -$802.0M | -$1.06B |